The vaccine candidate was antigenically similar to the circulating strain, prompting a robust neutralizing antibody response in early trials.

The researchers identified a new antigen that could improve the vaccine's effectiveness.

Researchers designed an antigene to bind the mutant BRCA1 sequence and silence its expression in affected cells.

The laboratory tested the blood samples for antigens associated with the new virus.

Researchers measured the antigenicity of the viral protein to predict vaccine effectiveness.

Early entomologists described the wing markings as antigenic, noting distinct male and female forms among several moth species.

The researchers studied the antigenic properties of the virus to design an effective vaccine.

The antigenized monoclonal antibodies were genetically altered to express epitopes from multiple pathogens and showed cross-reactive binding in vitro.

Researchers compared the antigenicities of several influenza strains to determine which would be most effectively targeted by the new vaccine.

The antigenerative activists argued that deliberately restricting births was the most ethical way to reduce environmental impact.